Sökning: onr:"swepub:oai:DiVA.org:oru-102187" >
Model-based predict...
Model-based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease
-
- Nilsson, Kristoffer (författare)
- The Swedish Institute for Health Economics, Lund, Sweden
-
- Andersson, Emelie (författare)
- The Swedish Institute for Health Economics, Lund, Sweden
-
- Persson, Sofie (författare)
- Lund University,Lunds universitet,Hälsoekonomi,Forskargrupper vid Lunds universitet,Health Economics,Lund University Research Groups,IHE – The Swedish Institute for Health Economics
-
visa fler...
-
- Karlsdotter, Kristina (författare)
- Boehringer Ingelheim AB, Stockholm, Sweden
-
- Skogsberg, Josefin (författare)
- Boehringer Ingelheim AB, Stockholm, Sweden
-
- Gustavsson, Staffan (författare)
- Boehringer Ingelheim AB, Stockholm, Sweden
-
- Jendle, Johan, 1963- (författare)
- Örebro universitet,Institutionen för medicinska vetenskaper,Boehringer Ingelheim AB
-
- Steen Carlsson, Katarina (författare)
- Lund University,Lunds universitet,Hälsoekonomi,Forskargrupper vid Lunds universitet,Health Economics,Lund University Research Groups,IHE – The Swedish Institute for Health Economics
-
visa färre...
-
(creator_code:org_t)
- 2022-12-02
- 2023
- Engelska.
-
Ingår i: Diabetes, obesity and metabolism. - : Wiley-Blackwell Publishing Inc.. - 1462-8902 .- 1463-1326. ; 25:3, s. 748-757
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
http://dx.doi.org/10... (free)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
visa färre...
Abstract
Ämnesord
Stäng
- AIM: To perform a model-based analysis of the short- and long-term health benefits and costs of further increased implementation of empagliflozin for people with type 2 diabetes and established cardiovascular disease (eCVD) in Sweden.MATERIALS AND METHODS: The validated Institute for Health Economics Diabetes Cohort Model (IHE-DCM) was used to estimate health benefits and 3-years' budget impact, and lifetime costs per quality-adjusted life year (QALY) gained of increased implementation of adding empagliflozin to standard of care (SoC) for people with type 2 diabetes and eCVD in a Swedish setting. Scenarios with 100%/75%/50% implementation were explored. Analyses were based on 30 model cohorts with type 2 diabetes and eCVD (n=131,412 at baseline) from national health data registers. Sensitivity analyses explored the robustness of results.RESULTS: Over 3 years, SoC with empagliflozin (100% implementation) vs. SoC before empagliflozin resulted in 7,700 total life years gained and reductions in cumulative incidence of cardiovascular deaths by 30% and heart failures by 28%. Annual costs increased by 6% from higher treatment costs and increased survival. Half of these benefits and costs are not yet reached with current implementation below 50%. SoC with empagliflozin yielded 0.37 QALYs per person, with an incremental cost-effectiveness ratio of €16,000 EUR per QALY vs. SoC before empagliflozin.CONCLUSIONS: Model simulations using real-world data and trial treatment effects indicated that a broader implementation of empagliflozin, in line with current guidelines for treatment of people with type 2 diabetes and eCVD, would lead to further benefits even in a short-term perspective.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Hälsovetenskap -- Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Health Sciences -- Health Care Service and Management, Health Policy and Services and Health Economy (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Nilsson, Kristof ...
-
Andersson, Emeli ...
-
Persson, Sofie
-
Karlsdotter, Kri ...
-
Skogsberg, Josef ...
-
Gustavsson, Staf ...
-
visa fler...
-
Jendle, Johan, 1 ...
-
Steen Carlsson, ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Endokrinologi oc ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Hälsovetenskap
-
och Hälso och sjukvå ...
- Artiklar i publikationen
-
Diabetes, obesit ...
- Av lärosätet
-
Örebro universitet
-
Lunds universitet